Compare Hims and Hers Health Inc (HIMS) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Verisign, Inc. — how do they compare? Hims and Hers Health Inc trades at $32.39 (market cap $7.57B), while Verisign, Inc. trades at $266.21 (market cap $25.26B). The key difference: Verisign, Inc. is far larger — about 3.3× Hims and Hers Health Inc's market cap, and Verisign, Inc. pays a 1.17% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | VRSN | |
|---|---|---|
Market Cap | $7.57B | $25.26B |
Sector | Health | Technology |
52-Week High | $66.18 | $310.00 |
52-Week Low | $14.52 | $211.49 |
Enterprise Value | $7.95B | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.
The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.
VeriSign (VRSN) trades at $277.60, down slightly by 0.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with EPS of $2.34 beating estimates, driven by 6.6% revenue growth. Analyst consensus is a Buy with a $325.25 price target, reflecting confidence in its domain registry monopoly and robust margins.
Outlook remains positive due to predictable revenue streams from .com and .net domains, though risks include AI disruption and contract renewals. Valuation multiples like P/E of 30.68 appear elevated, requiring sustained growth to justify. Investors should weigh high margins against debt levels and competitive threats for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
